Milind Desai, M.D., MBA, the director of clinical operations, Heart, Vascular & Thoracic Institute, Cleveland Clinic, discusses the recent approval of Camzyos, the first and only FDA-approved allosteric and reversible inhibitor selective for cardiac myosin that targets the underlying pathophysiology of obstructive hypertrophic cardiomyopathy (HCM). He also shares insight into what this treatment option means for obstructive HCM patients and the clinical impact of this approval.
#Camzyos
Milind Desai, MD MBA, is the Director of Clinical Operations of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic. He is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He holds the Haslam Family Endowed Chair in Cardiovascular Medicine. He has dual appointments in the Departments of Cardiovascular Medicine (Section of Cardiovascular Imaging) and Radiology. In addition, Dr. Desai is the Director of Center for Hypertrophic Cardiomyopathy, the Medical Director of the Center for Aortic Diseases, the Medical Director for Center for Radiation Heart Disease and an integral part of the Center for Valvular heart disease. He is an expert in multimodality cardiovascular imaging, having achieved the highest level of proficiency in all imaging modalities, including cardiac MRI, cardiac CT, echocardiography and nuclear cardiology. In addition, he serves on the multiple Heart, Vascular & Thoracic Institute councils, including Executive Council, Operations Council and Research Council. He also serves on the Cleveland Clinic Research Compliance Committee.